|
|
|
|
|
|
Program Overview
Program Format
Target Audience
Learning Objectives
Disclaimer
CME/CE Information
Credit Designation Nurses: The Institute for Johns Hopkins Nursing designates this activity for a maximum of 1.2 contact hours. Claim only those contact hours actually spent in the activity. Pharmacists: This program is approved for one (1) hour credit (0.1 CEUs) and is co-sponsored by the University of Tennessee College of Pharmacy who is approved by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. Program #: 064-999-05-250-H01.
Grievance Policy A participant, sponsor, faculty member or other individual wanting to file a grievance with respect to any aspect of a program sponsored or co-sponsored by the UTCOP may contact the Associate Dean for Continuing Education in writing. The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level of review.
Date of Release and Expiration
Responsibility Statement
Privacy Statement
Faculty Douglas A. Kerr, MD, PhD is an assistant professor of neurology with a joint appointment in the department of molecular microbiology and immunology. He specializes in transverse myelitis and multiple sclerosis. Dr. Kerr has established the Johns Hopkins Transverse Myelitis Center, which is the only such center in the entire world. The center utilizes the expertise of physicians and therapists from a variety of disciplines including neurology, neurosurgery, neuroradiology, rheumatology, rehabilitation medicine and urology for a comprehensive evaluation of transverse myelitis. Dr. Kerr also has research interest in determining the cause(s) of transverse myelitis, evaluating novel markers to help prognosticate outcomes in the acute phase, and in developing novel treatments. Dr. Kerr also investigates neural stem cells as a potential tool for functional recovery in patients with transverse myelitis and motor neuron disease. He has made significant discoveries concerning the basic molecular biology of neuronal apoptosis, especially in motor neurons of the spinal cord. J. Theodore Phillips, MD, PhD (Moderator) J. Theodore Phillips, MD, is the director of the Multiple Sclerosis Center at Texas Neurology in Dallas. He serves as a clinical associate professor of neurology at the University of Texas Southwestern Medical Center and as an attending neurologist at Baylor University Medical Center in Dallas. Dr. Phillips is a graduate of the University of Texas at Austin with special honors in chemistry, and received his MD and his PhD in immunology, and neurology residency training from the University of Texas Southwestern Medical Center at Dallas. He is a principal developer of a national registry for MS (MSTRAC) and is a principal investigator in several ongoing clinical treatment trials in MS. Shirley O'Leary, RN, MSCN Shirley O'Leary, RN, MSCN, practices with J. Theodore Phillips, MD, at the Multiple Sclerosis Center at Texas Neurology. Over the last 10 years she has been involved in all aspects of patient care, including MS research. She is a member of the International Organization of MS Nurses and the American Association of Neuroscience Nurses and has collaborated on several published MS articles. Julie Farace, RN, BSN Julie Farace, RN, BSN, CNRN is on staff at The Johns Hopkins Hospital in the Department of Radiology. She has worked for The Johns Hopkins Transverse Myelitis and Multiple Sclerosis Centers, and she comes from a strong background in neurosciences that ranges from critical care to the outpatient setting. Her background also includes experience coordinating research studies for MS and TM under the direction of Dr. Douglas Kerr. She is a member of the American Association of Neuroscience Nursing. Frederick E. Munschauer, MD Frederick E. Munschauer, MD, is a board-certified specialist in neurology and internal medicine with a subspecialty in critical care. He is a professor of clinical neurology and internal medicine at the State University of New York at Buffalo School of Medicine and Biomedical Sciences and serves as interim chairman of the department of neurology, as well as acting chief of The Jacobs Neurological Institute of Kaleida Health, Buffalo, New York. Dr. Munschauer received his medical degree from McGill University, Montreal, Quebec, Canada, and completed an internship and residency in internal medicine and a residency in neurology at The Johns Hopkins Hospital, Maryland, USA. He also completed a fellowship in neurological and neurosurgical intensive care at The National Hospital for Nervous Disease, London, UK. Dr. Munschauer is a member of the American Academy of Neurology, the American Heart Association, the American Medical Association, the American Society of Neuroimaging, and the Society of Critical Care Medicine. Dr. Munschauer has researched extensively in the use of interferon-b1a (IFN-b1a) as treatment for relapsing-remitting multiple sclerosis (MS) and was coinvestigator of phase III clinical trials and the CHAMPS study. His publications include the phase III clinical trial results, as well as the rationale for early treatment of MS with IFN-b1a, and managing side effects of IFN-b1a in patients. Dr. Munschauer lectures nationally and internationally on the use of IFN-b1a in patients with MS and is considered one of the leaders in the field of MS treatment. Shirley O'Leary, RN, MSCN, practices with J. Theodore Phillips, MD, at the Multiple Sclerosis Center at Texas Neurology. Over the last 10 years she has been involved in all aspects of patient care, including MS research. She is a member of the International Organization of MS Nurses and the American Association of Neuroscience Nurses and has collaborated on several published MS articles. Mariko Kita, MD Dr. Kita attended medical school at the Northwestern University School of Medicine, her residency in neurology at the Hospital of the University of Pennsylvania, internship in internal medicine at Northwestern Memorial Hospital, and a fellowship in neuroimmunology at Mt. Zion Multiple Sclerosis Center, University of California School of Medicine. Dr. Kita is currently Director of the Virginia Mason Multiple Sclerosis Center and is board certified by the American Board of Psychiatry and Neurology.
Faculty Disclosures Dr. Douglas Kerr has received grant and research support from the NIH. Dr. Frederick E. Munschauer has received grants and research support from Biogen Idec, Bristol-Myers Squibb, Pfizer, Merck, AstraZeneca, Sanofi, National Institute of Health, and the IHA Foundation. He has served as a consultant for Biogen Idec and has received honorarium from Biogen Idec, Sanofi-Synthelabo, and Pfizer. Julie Farace, RN, BSN has no relationships to disclose. Dr. J. Theodore Phillips has received honorarium from Biogen Idec, Ilex, Neurocrine Biosciences, and Serono Dr. Mariko Kita has received grants and research support from Serono, Biogen Idec, Teva Neuroscience. She has served as a consultant for Serono, Biogen Idec, Teva Neuroscience, and Berlex. Shirley O'Leary, RN, MSCN has received honorarium from Biogen Idec.
Off-Label Discussion Rituxan (rituximab), Zenapax (daclizumab), Campath (alemtuzumab), combination (natalizumab and Rebif [interferon beta 1-a]), combination (natalizumab and Betaseron [interferon beta-1b]), combination (natalizumab and mitoxantrone), combination (natalizumab and Copaxone [glatiramer acetate]) This educational program is supported through an educational grant from Biogen Idec and Elan Pharmaceuticals. © 2005 The Johns Hopkins University School of Medicine, The Institute of Johns Hopkins Nursing and The University of Tennessee College of Pharmacy. All rights reserved. |
|
||||||||||||||||
 | |||||||||||||||||||
